INFLIXIMAB FOR TREATMENT OF COPD - A PILOT STUDY

英夫利昔单抗治疗慢性阻塞性肺病 - 一项试点研究

• 批准号: 7376932
• 负责人: STEVEN M SCHARF
• 金额: $ 0.1万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376932
• 关键词: INFLIXIMAB; TREATMENT; COPD; PILOT; STUDY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic obstructive pulmonary disease (COPD) is a devasting complication of cigarette smoking. In addition to severe problems in lung function, there is evidence that inflammation plays a major role in leading to disability in COPD. Elevation of an inflammatory factor in COPD, tumor necrosis factor alpha (TNFa), could cause severe weight loss, muscle weakness and wasting. These findings are a grave sign in COPD patients. We will be performing a pilot study on 12 COPD patients using a drug called infliximab, an antibody against TNF-alpha. We will be monitoring adverse events and a number of outcomes that could indicate clinical improvement. These include lung function, muscle strength, exercise performance, body composition, and quality of life. Data gathered from this pilot study will be used to design a randomized clinical trial of a novel new therapy for COPD in a larger group of patients.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。慢性阻塞性肺疾病（COPD）是吸烟的一种毁灭性并发症。除了严重的肺功能问题外，有证据表明炎症在导致COPD残疾方面起着重要作用。COPD中炎症因子肿瘤坏死因子α（TNF α）的升高可能导致严重的体重减轻、肌肉无力和消瘦。这些发现是COPD患者的严重体征。我们将对12名COPD患者进行一项试点研究，使用一种名为英夫利昔单抗的药物，一种抗TNF-α的抗体。我们将监测不良事件和一些可能表明临床改善的结果。这些包括肺功能，肌肉力量，运动表现，身体成分和生活质量。从这项初步研究中收集的数据将用于设计一项在更大患者群体中进行的COPD新型新疗法的随机临床试验。